AVETA

Hormone-free solution for vaginal atrophy

Vaginal atrophy, now known as Genitourinary Syndromes of Menopause (GSM), is a globally challenging condition for 80 % of menopausal women and breast cancer survivors. It is associated with thinning and inflammation of the vaginal walls due to lower oestrogen levels. Current treatment options: Local hormone therapy and moisturisers are poorly tolerated due to side effects, safety concerns, and the cumbersome dosing burden, which, if not adhered to, impacts efficacy significantly. The EIC-funded AVeta project has developed a revolutionary device, VITA AV, that is hormone-free, natural, safe, accessible, and suitable for all women suffering from GSM. Treatment provides long-lasting symptom relief and, as it is based on the body’s natural healing response, presents with no side effects, restoring vaginal tissue health. It will be clinically prescribed and administered in an outpatient setting or a physician’s office. With a pathway to reimbursement, this will be accessible and suitable for all women.